Rutgers-led Team Launches Science and Medicine Research Initiative to Transform Health Care in New Jersey

Leaders from health care, pharma, public policy, and government discuss plans to hasten clinical trials, develop new therapies and train a new scientific workforce in the Garden State

Newswise — New Jersey residents will have access to the newest clinical trials and medical breakthroughs as a result of an innovative consortium between Rutgers University, Princeton University and the New Jersey Institute of Technology.

At an event Thursday organized by that consortium, the New Jersey Alliance for Clinical and Translational Science (NJACTS), thought leaders from academia, health care, government and the pharmaceutical industry discussed the future of scientific and clinical trial innovation in the state. These new innovations will result from a $33-million grant from the National Institutes of Health (NIH).

“We aim to shorten the time it takes to get innovative drugs in the market, train the next generation of translational scientists, engage patients and communities, integrate special and underserved populations, advance the use of big data information and increase the quality and efficiency in translational research,” said Reynold Panettieri, vice chancellor for translational medicine and science, and director of Rutgers Institute for Translational Medicine and Science.

Panelists at Thursday’s event, termed “The Evolution of a Revolution in Health”, discussed potential solutions for unmet health care needs in New Jersey and how the private sector can collaborate with academic researchers to develop cutting-edge treatments.

“This grant is a huge win for New Jersey and shows our eagerness to expand clinical research to improve the health for more than nine million people,” said Brian Strom, chancellor of Rutgers Biomedical and Health Sciences and executive vice president for health affairs for Rutgers.

Other discussions revolved around how partners involved in the new grant will attract and train new researchers to the state, use machine learning and precision medicine to diagnose and treat diseases, as well as to expand access to clinical trials for New Jersey residents.

“Collaborative partnerships like these are important to the mission of New Jersey’s health care systems and a testament to the amazing work we can do when brilliant minds come together to effect change,” said Barry Ostrowsky, president and CEO, RWJBarnabas Health.

“The discoveries that will come from the collaborations of these great institutions will help minority groups and break barriers in clinical advancements, which will go a long way in changing policies that directly affect New Jerseyans,” said Heather Howard, a lecturer in public affairs at Princeton University and a former commissioner of the New Jersey Department of Health and Senior Services.

During a panel discussion on public policy, New Jersey Assemblywoman Nancy Pinkin (18th District) emphasized the importance of streamlining health data so researchers and health care partners can grow medical advancements in the state. Assemblywoman Pinkin, who is the vice chair of the Assembly’s Health and Senior Services Committee, added that all stakeholders must strive to reduce the disparities in health care delivery.

Other speakers at the event included Rutgers President Robert Barchi and Rutgers-New Brunswick Chancellor Christopher Molloy.

The NJACTS initiative is the first NIH-funded program of its kind in the New Jersey. It is part of a nationally supported network of more than 50 programs at medical research institutions that collaborate to speed the translation of research discoveries into improved patient care. 

Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Showing results

110 of 4573